Three New Clinical Trials to Begin in 2015, including a Global, Randomized Trial of Iclusig vs. Nilotinib in Second-Line CML CAMBRIDGE, Mass.–(BUSINESS WIRE)–Jan. 13, 2015– ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced its key strategic objectives for 2015, details of which will be presented at the 33rd Annual J.P. Morgan Healthcare Conference on January 14, 2015 in San Francisco, California. These objectives are focused on expanded commercial, research and development, and new business development initiatives that together are expected to lea… Read more

Shares of Ariad Pharmaceuticals closed yesterday at $6.97 . ARIA has a 1-year high of $9.83 and a 1-year low of $4.90. The stock’s 50-day moving average is $6.90 and it’s 200-day moving average is $6.09.

On the ratings front, Ariad Pharmaceuticals has been the subject of a number of recent research reports. In a report published on January 7, analyst Reni Benjamin from H.C. Wainwright reiterated a Buy rating on ARIA, with a price target of $8, which represents a potential upside of 14.8% from where the stock is currently trading. Separately, on December 11, Credit Suisse`s Jason Kantor downgraded Ariad Pharmaceuticals shares to Sell and has a price target of $6.

In total, one research analyst has rated the stock with a Sell rating, One research analyst has assigned a Hold rating and 2 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $6.97 which is -11.5% under where the stock closed yesterday.

Ariad Pharmaceuticals Inc is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules.